Andersons pediatric cardiology 2350
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (79.45 KB, 3 trang )
permissibilityofwithdrawalordiscontinuationofdevices,1472–1474
resourceallocationof,1468
risksofgenetictestingandautonomyconsiderationsof,1467
shareddecision-makinganddecisionauthority,1471–1472
socialjusticeconsiderationsinpediatriccardiology,1477–1479
Ethicaljustifications,1473–1474
Ethylsuccinate,forrheumaticfeverprevention,1016t
Etomidate,1549
EuropeanCongenitalHeartSurgeonsAssociationDatabase,1511t–1514t
EuropeanRegistryforICDandCRTDevicesinPediatricsandAdultswith
CongenitalHeartDisease,1511t–1514t
EuropeanRegistryforPatientswithMechanicalCirculatorySupport,1511t–
1514t
Eustachianvalve,19,20f
indiagnosticcatheterization,245
Evidence,levelsof,419,419t
Excitation,incardiomyocyte,75–77,76f
EXCORcannulas,inshort-termmechanicalcirculatorysupport,1207
Exercise
bloodpressureand,1123–1124
capacity,impaired,inFontancirculation,1321–1324,1321f–1323f
followingcardiactransplantation,1235–1236
forFontanfailure,1345
programs,foruniventricularheart,1348–1349,1349f–1350f
pulmonaryresponseto,384–385,385f
recommendationsfor,801–802,801f
for“well”Fontan,1339
Exercisephysiology,379,380f
bloodflowdistributionand,382–383,383f
cardiacoutputsurrogatesand,383–384,384f
cellularmetabolismand,379–381,381f
heartandlungasserviceorgansand,381–382,382f
oxygenpulseand,384
pulmonaryresponsetoexerciseand,384–385,385f
Exercisetesting,379–402
analysersofrespiratorygasexchangefor,389,390f
bloodpressuremonitorsfor,390
forcancertherapy-relatedcardiotoxicity,1171
contraindicationsto,399,399b
dataobtainedduring,391–398
aerobiccapacityas,391–392,392t
bloodpressureresponseas,393–394
cardiacoutputas,393,393t
electrocardiographic,394,394b,395f–396f
evaluationofmyocardialischemiaand,394
nuclearperfusionimagingand,396–397,397f
positron-emissiontomographyand,397–398
pulmonaryfunctionas,393
rateofworkas,391
stressechocardiographyand,398
electrocardiographicrecordersfor,388
environmentin,386
ergometersfor,387–388,387t
cycle,388,389f
treadmill,387,388f
indicationsfor,390–391,391b
laboratoryrequirementsfor,386–387
patientpreparationfor,386–387,386f
physiologyand,Exercisephysiology
forpulmonaryhypertension,1387
pulseoximetersfor,390
safetyprecautionsfor,386,386b
spirometryand,389–390
terminationof,reasonsfor,399,399b
usesof,399–402
Exon-intronjunctionselection,68
Expandedpolytetrafluoroethylenegraft,1278–1279,1279f
Extracardiacanomalies
centralnervoussystem,452
gastrointestinalsystem,453
genitourinarysystem,454
pulmonarysystem,452
ExtracardiacFontan,1301,1301f
Extracardiacinterventions,withinterventionaltechniques,268–275
Extracellularmatrixdisorders,cardiacinvolvementin,1077,1098–1102
Extracorporealcardiopulmonaryresuscitation,foracutecirculatoryfailure,1188
Extracorporeallifesupport(ECLS),foracutecirculatoryfailure,1185–1191
basicprinciplesof,1185
bedsidecareon,1191
completemechanicalsupportin,1186–1187
contraindicationsfor,1185–1186
echocardiographyon,1189,1190f,1190t
extracorporealcardiopulmonaryresuscitationand,1188
familypreparationfor,1191
inhigh-riskpatientgroups,1188
indicationsfor,1185
leftheartdecompressionon,1189
mechanicalsupport,choiceandmodeof,1186,1186t
ongoingreassessmentin,1189,1189f
partialmechanicalcirculatorysupportin,1187–1188
risksandadverseeventsduring,1189
simulationin,1188–1189
survivalafter,1191
timingof,1186
transportingpatientson,1188
weaningfrom,1190–1191
ExtracorporealLifeSupportOrganizationRegistry,1511t–1514t
Extracorporealmembraneoxygenation(ECMO)
foracutecirculatoryfailure,1186,1187t
formyocarditis,1176
